QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.017814v1 69/1/236    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langmead, C. J. Articles by Herdon, H. J. Search for Related Content PubMed PubMed Citation Articles by Langmead, C. J. Articles by Herdon, H. J.

Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M₁ Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist

Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, United Kingdom (C.J.L., V.A.H.F., I.T.F., C.L.B., M.D.W., H.J.H.); and Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia (A.C.)

4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chloride (AC-42) is a selective agonist of the muscarinic M₁ receptor previously suggested to interact with an "ectopic" site on this receptor. However, the pharmacological properties of this site (i.e., whether it overlaps to any extent with the classic orthosteric site or represents a novel allosteric site) remain undetermined. In the present study, atropine or pirenzepine significantly inhibited the ability of either carbachol or AC-42 to stimulate inositol phosphate accumulation or intracellular calcium mobilization in Chinese hamster ovary (CHO) cells stably expressing the human M₁ receptor. However, the interaction between either of these antagonists and AC-42 was characterized by Schild slopes significantly less than unity. Increasing the concentrations of atropine revealed that the Schild regression was curvilinear, consistent with a negative allosteric interaction. More direct evidence for an allosteric mode of action of AC-42 was obtained in [³H]N-methylscopolamine ([³H]NMS) binding studies, in that both AC-42 and the prototypical modulator gallamine failed to fully inhibit specific [³H]NMS binding in a manner that was quantitatively described by an allosteric model applied to both modulator data sets. Furthermore, AC-42 and gallamine significantly retarded the rate of [³H]NMS dissociation from CHO-hM₁ cell membranes, conclusively demonstrating their ability to bind to a topographically distinct site to change M₁ receptor conformation. These data provide the first direct evidence that AC-42 is an allosteric agonist that activates M₁ receptors in the absence of the orthosteric agonist.

Received for publication August 8, 2005.

Accepted for publication October 5, 2005.

Address correspondence to: Dr. Christopher J. Langmead, Psychiatry CEDD, GlaxoSmithKline, Third Ave., Harlow, Essex, CM19 5AW, UK. E-mail: christopher.j.langmead{at}gsk.com

This article has been cited by other articles:

				L. Wang, B. Martin, R. Brenneman, L. M. Luttrell, and S. Maudsley Allosteric Modulators of G Protein-Coupled Receptors: Future Therapeutics for Complex Physiological Disorders J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 340 - 348. [Abstract] [Full Text] [PDF]

				G. Lebon, C. J. Langmead, B. G. Tehan, and E. C. Hulme Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors Mol. Pharmacol., February 1, 2009; 75(2): 331 - 341. [Abstract] [Full Text] [PDF]

				R. L. Thomas, R. Mistry, C. J. Langmead, M. D. Wood, and R. A. J. Challiss G Protein Coupling and Signaling Pathway Activation by M1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 365 - 374. [Abstract] [Full Text] [PDF]

				H. Salah-Uddin, D. R. Thomas, C. H. Davies, J. J. Hagan, M. D. Wood, J. M. Watson, and R. A. J. Challiss Pharmacological Assessment of M1 Muscarinic Acetylcholine Receptor-Gq/11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 869 - 874. [Abstract] [Full Text] [PDF]

				L. T. May, V. A. Avlani, C. J. Langmead, H. J. Herdon, M. D. Wood, P. M. Sexton, and A. Christopoulos Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2007; 72(2): 463 - 476. [Abstract] [Full Text] [PDF]

				E. Machova, J. Jakubik, E. E. El-Fakahany, and V. Dolezal Wash-Resistantly Bound Xanomeline Inhibits Acetylcholine Release by Persistent Activation of Presynaptic M2 and M4 Muscarinic Receptors in Rat Brain J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 316 - 323. [Abstract] [Full Text] [PDF]

				T. A. Spalding, J.-N. Ma, T. R. Ott, M. Friberg, A. Bajpai, S. R. Bradley, R. E. Davis, M. R. Brann, and E. S. Burstein Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation Mol. Pharmacol., December 1, 2006; 70(6): 1974 - 1983. [Abstract] [Full Text] [PDF]